本文選題：菊粉果聚糖 + 代謝綜合征��； 參考：《甘肅中醫(yī)藥大學(xué)》2016年碩士論文

【摘要】：目的:代謝綜合征是各種心血管危險因素組成的臨床綜合征,其臨床表現(xiàn)包括腹型肥胖、高脂血癥、高血糖或糖尿病及高血壓,其具體機制是胰島素抵抗和炎癥反應(yīng),其中肥胖是代謝綜合征和胰島素抵抗的最主要的危險因素。菊粉果聚糖是一種從植物根莖中提煉出的多聚果糖。既往研究顯示,菊粉果聚糖有降低血脂、血糖的作用,并廣泛用于食品添加劑,以代替脂質(zhì)成分減少熱量攝入。然而,其在代謝綜合征患者中的作用研究較少。本項研究的目的是觀察不同劑量菊粉果聚糖對代謝綜合征患者血脂、血糖及體重指數(shù)的影響,旨在評價菊粉果聚糖在代謝綜合征患者中的應(yīng)用價值。方法:本項研究采用隨機對照試驗設(shè)計,連續(xù)選入2015年3月至7月就診于甘肅省人民醫(yī)院心內(nèi)科的代謝綜合征患者300例,隨機分為3組,每組100例,A組[高劑量(20g/d)菊粉果聚糖治療組],B組[低劑量(10g/d)菊粉果聚糖治療組],C組(單純飲食控制組),干預(yù)3個月,采集患者的基線資料,分別于入組時、治療3月時收集所有患者清晨空腹血標(biāo)本,比較三組患者干預(yù)前后體重指數(shù)、腹圍、臀圍、血脂、血糖、收縮壓等指標(biāo)。結(jié)果:三組患者基線資料無統(tǒng)計學(xué)差異。治療前后3組患者體重指數(shù)及腹圍、臀圍無明顯差異。經(jīng)3個月治療后,結(jié)果顯示,菊粉果聚糖治療組患者血清總膽固醇(3.61±1.10vs.3.73±0.81vs.4.65±1.17,P=0.038,P=0.022,P=0.031),血清甘油三酯水平(1.59±0.69vs.1.79±1.14vs.1.57±0.72,P=0.041,P=0.011,P=0.031),低密度脂蛋白(3.02±0.84vs.3.02±0.94vs.3.14±0.89 P=0.042,P=0.026,P=0.041),血糖(5.11±0.49vs.5.36±1.37 vs.5.35±0.98 P=0.041,P=0.031,P=0.021)及收縮壓(126.72±11.98 vs.124.45±13.6 vs.130.36±19.50 P=0.033,P=0.034,P=0.015)水平低于單純飲食控制組,高密度脂蛋白(1.30±0.22 vs.1.20±0.27vs.0.29±0.62 P=0.026,P=0.033,P=0.025)水平高于單純飲食控制組。進(jìn)一步分析顯示,治療前后A、B兩組患者總膽固醇(A組:4.57±0.93vs.3.61±1.10,P=0.045;B組:4.85±1.46vs.3.73±0.81,P=0.049)、甘油三酯(A組:1.76±0.57vs.1.59±0.69,P=0.046;B組:1.94±1.12vs.1.79±1.14,P=0.048)、高密度脂蛋白(A組:0.28±0.33vs.1.30±0.22,P=0.036;B組:0.32±0.25vs.1.20±0.27,P=0.016)、低密度脂蛋白(A組:3.06±0.82vs.3.02±0.84,P=0.035;B組:3.04±0.88 vs.3.02±0.94,P=0.022)、血糖(A組:5.21±1.35vs.5.11±0.49,P=0.010;B組:5.39±0.90 vs.5.36±1.37,P=0.019).及收縮壓(A組:130.72±11.20vs.130.72±11.20,P=0.021;B組:131.45±13.11vs.124.45±13.62,P=0.015)水平均有統(tǒng)計學(xué)差異。C組患者治療前后血脂、血糖及收縮壓無統(tǒng)計學(xué)差(P0.05)。治療后A組與B組(P=0.008),B組與C組(P=0.002),A組與C(P=0.001)均有統(tǒng)計學(xué)差異。結(jié)論:服用菊粉可調(diào)節(jié)代謝綜合征肥胖患者的血糖、血脂水平并對降低心血管疾病風(fēng)險有潛在益處。
[Abstract]:Objective: metabolic syndrome is a clinical syndrome composed of various cardiovascular risk factors. Its clinical manifestations include abdominal obesity, hyperlipidemia, hyperglycemia or diabetes mellitus and hypertension. Obesity is the most important risk factor for metabolic syndrome and insulin resistance. Inulin is a polyfructose extracted from plant roots. Previous studies have shown that inulin can reduce blood lipids and blood sugar and is widely used as food additive to reduce calorie intake instead of lipids. However, its role in metabolic syndrome patients is less studied. The purpose of this study was to observe the effects of different doses of inulin on blood lipids, blood glucose and body mass index (BMI) in patients with metabolic syndrome, and to evaluate the value of inulin in patients with metabolic syndrome. Methods: a randomized controlled trial was used to select 300 patients with metabolic syndrome from March to July 2015 in Department of Cardiology, Gansu Provincial people's Hospital, and were randomly divided into 3 groups. Group A [high dose 20 g / d] group B [low dose 10 g / d] group C (diet control group, intervention 3 months), baseline data of patients were collected. Fasting blood samples of all patients were collected at 3 months after treatment. Body mass index, abdominal circumference, hip circumference, blood lipid, blood glucose and systolic blood pressure were compared before and after intervention. Results: there was no statistical difference in baseline data among the three groups. There was no significant difference in body mass index, abdominal circumference and hip circumference between the three groups before and after treatment. 緇，

本文編號：1942629